Sofgen Pharma S.A PROCF
0.00
0.00
NaN
as of 24 Sep
- Market cap
- $114.0M
- P/E
- 0.0×
Follow PROCF
| Dec '23 | Sep '23 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
10.54 | 7.81 | 7.17 | 17.37 |
+8 more quarters Free account |
P/S ratio |
1.02 | 0.89 | 1.09 | 1.14 | |
P/FCF ratio |
5.78 | 11.34 | 0.00 | 0.00 | |
P/Operating CF |
11.78 | 7.65 | 21.28 | 146.72 | |
P/B ratio |
0.00 | 9.43 | 13.57 | 88.22 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.72 | 1.55 | 1.77 | 1.80 | |
EV/EBITDA |
8.08 | 30.13 | 29.29 | 26.02 | |
EV/Operating CF |
6.77 | 9.79 | 31.02 | 58.54 | |
EV/FCF |
9.74 | 19.72 | (74.98) | (34.43) | |
Quick Ratio |
0.34 | 0.83 | 0.64 | 0.60 | |
Current Ratio |
0.64 | 1.47 | 1.21 | 1.15 | |
Net Debt/EBITDA |
6.49 | 14.77 | 14.03 | 38.03 | |
Debt/Assets |
67.88% | 58.98% | 59.55% | 65.30% | |
Debt/Equity |
(435.78) | 7.65 | 9.12 | 55.80 | |
Asset Turnover |
0.93 | 0.84 | 0.83 | 0.87 | |
Operating CF/Net income |
(25.72) | 5.78 | 0.76 | 0.47 | |
Capex/Depreciation |
(2.39) | (1.54) | (1.82) | (1.31) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
44.31% | 46.63% | 41.89% | 50.84% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.46) | (0.45) | (0.38) | (0.37) | |
Graham Number |
0.00 | 1.98 | 2.07 | 0.55 | |
Earnings Yield |
9.49% | 12.81% | 13.95% | 5.76% | |
Free Cash Flow Yield |
17.31% | 8.82% | (2.17%) | (4.60%) | |
Revenue per Share |
1.10 | 1.17 | 1.09 | 0.83 | |
Operating CF per Share |
0.36 | 0.47 | 0.20 | 0.03 | |
Capex per Share |
(0.12) | (0.08) | (0.08) | (0.05) | |
Free Cash Flow per Share |
0.24 | 0.39 | 0.12 | (0.02) | |
Cash per Share |
0.24 | 0.26 | 0.20 | 0.23 | |
Shareholders Equity per Share |
(0.01) | 0.38 | 0.32 | 0.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.01) | 0.38 | 0.32 | 0.05 | |
Free Cash Flow |
24.31 | 39.71 | 12.57 | (1.76) | |
Working Capital |
(157.92) | 95.42 | 51.67 | 35.38 | |
Capital Expenditures |
(12.39) | (7.68) | (7.86) | (4.86) | |
Net Current Asset Value |
(197.59) | (161.75) | (163.14) | (167.70) | |
EV/EBIT |
10.12 | 181.32 | 92.52 | 67.57 | |
Capex to Sales |
0.11 | 0.06 | 0.07 | 0.06 | |
Net Profit Margin |
(1.28%) | 6.92% | 24.49% | 7.87% | |
Price to Operating Income |
6.00 | 104.25 | 56.89 | 42.71 | |
| Other line items | |||||
Average Receivables |
115.64 | 136.17 | 128.37 | 113.96 | |
Average Payables |
— | 92.52 | 88.28 | 75.04 | |
Average Inventory |
100.79 | 99.30 | 101.35 | 98.75 | |
Average Assets |
457.51 | 484.86 | 480.46 | 462.49 | |
Average Common Equity |
(18.93) | 13.97 | 1.23 | (7.24) |
Columns are period end dates